Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advanced Magnetics’ Combidex MRI Agent Will Get Committee Review

This article was originally published in The Pink Sheet Daily

Executive Summary

Imaging agent has a March 30, 2005 user fee date for use in differentiating metastatic and non-metastatic lymph nodes in at-risk cancer patients.

You may also be interested in...



Fate Of AstraZeneca's Iressa To Be Discussed By Advisory Cmte. March 4

FDA will seek input from its Oncologic Drugs Advisory Committee on whether Iressa's accelerated approval should be withdrawn after the non-small cell lung cancer agent failed to show a survival benefit in a confirmatory trial.

Fate Of AstraZeneca's Iressa To Be Discussed By Advisory Cmte. March 4

FDA will seek input from its Oncologic Drugs Advisory Committee on whether Iressa's accelerated approval should be withdrawn after the non-small cell lung cancer agent failed to show a survival benefit in a confirmatory trial.

Advanced Magnetics Combidex “Complete Response”

Advanced Magnetics' Combidex NDA has a user fee goal date of March 30, 2005

Topics

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel